Baseline characteristics of the patients studied
| Characteristic | PVAC | Placebo |
|---|---|---|
| (n = 18) | (n = 18) | |
| DMARDs, disease modifying antirheumatic drugs; CRP, C reactive protein; HAQ, Health Assessment Questionnaire; PASI, Psoriasis Activity and Severity Index. | ||
| Age (years), mean (SD) | 40.6 (8.8) | 51.8 (11.8) |
| Female sex, No (%) | 6 (33) | 10 (56) |
| Duration of psoriasis (years), median (range) | 13 (1–35) | 20.5 (2–41) |
| Duration of PsA (years), median (range) | 9 (1–20) | 10 (2–40) |
| DMARDs (before washout) at onset, No (%) | 4 (22) | 11 (61) |
| Methotrexate (before washout) at onset, No (%) | 1 (6) | 10 (56) |
| Asymmetric oligoarticular disease, No (%) | 10 (56) | 3 (17) |
| Polyarticular disease, No (%) | 8 (44) | 15 (83) |
| Axial disease, No (%) | 7 (39) | 7 (39) |
| Erosions on hand/feet radiographs, No (%) | 6 (33) | 7 (39) |
| Tender joint count, median (range) | 15.5 (4–42) | 16.5 (5–50) |
| Swollen joint count, median (range) | 9.5 (3–27) | 11.5 (3–33) |
| Patient global assessment, median (range) | 2.5 (2–4) | 2 (1–4) |
| Physician global assessment, median (range) | 3 (1–4) | 3 (1–4) |
| Patient pain score, mean (SD) | 46.1 (19.9) | 46.7 (24.4) |
| CRP (normal<1 mg/l), median (range) | 7.5 (2.0–39.0) | 9.5 (1.0–62.0) |
| HAQ, median (range) | 0.875 (0.0–1.625) | 0.75 (0.0–2.5) |
| PASI, median (range) | 2.8 (0.2–11.7) | 2.5(0.5–18.6) |